Recent headlines discussing various implications of the federal 340B Drug Pricing Program (340B) have spurred legislators’ interest. But what is 340B?
Although copay adjustment programs might encourage patients to look for cheaper therapeutic alternatives before turning to a more expensive treatment, they can be problematic for individuals whose plans involve high cost-sharing or co-insurance.
